In­dus­try, FDA be­gin to ham­mer out PDU­FA VII de­tails

5 years ago
FDA+

Bris­tol My­er­s' top hema­tol­ogy ex­ec is on his way out — right on the heels of a $6B CVR im­plo­sion

5 years ago
People

Am­gen tops cost watch­dog's price gougers list based on 'un­sup­port­ed' in­creas­es for En­brel with­out mean­ing­ful da­ta

5 years ago
Pharma

No­var­tis gets break­through des­ig­na­tion for Xo­lair suc­ces­sor, set­ting up spot­light for PhI­II read­out lat­er this year

5 years ago
FDA+

News brief­ing: Pre­ci­sion Med­i­cine Group ac­quires cell and gene ther­a­py-fo­cused ser­vices firm Project Far­ma; ...

5 years ago
News Briefing

As ven­ture fund­ing in on­col­o­gy flour­ish­es, neu­ro has seen shal­low­er pock­ets. A Eu­ro­pean in­vestor wants to change that

5 years ago
Financing

R&D ex­ec faces up to 10 years in prison on charges he stole “thou­sands” of top se­cret re­search doc­u­ments from ...

5 years ago
People
R&D

Fu­ji­film dou­bles down on Boston foothold, rent­ing some ma­jor legroom to chase cell and gene ther­a­pies

5 years ago
Financing
Manufacturing

Chris Garabe­di­an's first Xon­toge­ny com­pa­ny, Lan­dos Bio­phar­ma, preps a nine-fig­ure IPO as lead pro­gram heads to PhI­II

5 years ago
Financing

A much-hyped CV drug failed, re­peat­ed­ly. Now, in­vestors are bet­ting near­ly $200M on one last PhI­II bid

5 years ago
R&D

Janet Wood­cock to be act­ing FDA com­mis­sion­er while Biden team fi­nal­izes nom­i­nee — re­ports

5 years ago
People
FDA+

Mark Cuban jumps out of the Shark Tank and in­to gener­ic phar­ma with a plan to of­fer dirt-cheap drugs

5 years ago
People

Covid-19 roundup: Alex­ion's C5 in­hibitor Ul­tomiris miss­es the PhI­II bar; Lon­za in wait­ing game to use in­gre­di­ents in ...

5 years ago
Coronavirus

#JPM21: Avid­i­ty CSO Art Levin runs full speed to the clin­ic with 'dream' an­ti­body oligonu­cleotide con­ju­gate ther­a­py

5 years ago
R&D

J&J on track to roll out sin­gle-shot Covid-19 vac­cine in March, Paul Stof­fels con­firms, al­though man­u­fac­tur­ing de­lays ...

5 years ago
Coronavirus

Paint­ing by the num­bers, Sana founders carve up a gi­ant uni­corn-sized IPO — for a biotech that has­n't quite made it ...

5 years ago
Financing

Pfiz­er's in­vest­ment fund is mak­ing waves in VC — in­clud­ing a $25M bet on IBD play­er Vedan­ta Bio­sciences

5 years ago
Financing

News brief­ing: Mer­ck picks up SHP2 op­tion from Tai­ho-As­tex deal; Taysha ex­pands part­ner­ship with UT South­west­ern

5 years ago
News Briefing

Acor­da of­floads man­u­fac­tur­ing op­er­a­tions to Catal­ent for $70M amid lat­est re­struc­tur­ing to keep the ship afloat

5 years ago
Deals
Manufacturing

#JPM21: Al­bert Bourla pre­pares Pfiz­er to set­tle in to next phase post-Up­john, but that does­n't mean he's rul­ing out ...

5 years ago
People
Pharma

IDO on the re­bound? Dan­ish out­fit IO Biotech hopes so with over­sub­scribed Se­ries B one month af­ter BTD in melanoma

5 years ago
Financing

Adap­ti­m­mune 'ready for prime­time' as it pre­pares to launch T cell ther­a­py for sar­co­ma, CEO Adri­an Raw­cliffe says

5 years ago
Cell/Gene Tx
Manufacturing

A long­time Pfiz­er chief's ul­tra-qui­et biotech re-emerges with new cash and plans for the clin­ic

5 years ago
Startups

What can a 157-year-old phar­ma gi­ant bring to the ta­ble of cell and gene ther­a­pies? Quite a bit, Bay­er says

5 years ago
Pharma
Cell/Gene Tx
First page Previous page 747748749750751752753 Next page Last page
A service from the Financial Times